---
title: "Varegacestat (AL102) in Desmoid tumors: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Clinical presentation - signs and symptoms. Topics: Variability of presentation: asymptomatic to symptomatic tumors, Tumor-related signs: unexplained bump or mass, Pain: tumor pain, Neurological symptoms: nerve pain and paresthesia, and 5 further topics. 9 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Variability of presentation: asymptomatic to symptomatic tumors

> “Symptom presentation among DTF patients, however, is highly variable, ranging from no symptoms at all to extreme pain and functional limitations, regardless of tumour behaviour or size.”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

> “While some people with desmoid tumors do not experience symptoms, others may experience pain, swelling, difficulty sleeping and reduced mobility. Symptoms largely depend on the location of the tumor and the extent of invasion or compression of surrounding tissue.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.2.1.6-2"></a>

### Tumor-related signs: unexplained bump or mass

> “Signs and symptoms reported at diagnosis included an unexplained bump (60%, 238/399), pain (57%, 226/399), and fatigue (14%, 54/399).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

<a id="topic-2.2.1.6-3"></a>

### Pain: tumor pain

> “Pain was the most common reported symptom (57.4%).”
> “DT-related symptoms that were most documented in the clinical notes were tumor pain ( n = 85, 57.4%), fullness ( n = 23, 15.5%), loss of function ( n = 22, 14.9%), and paresthesia ( n = 17, 11.5%).”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

> “The patients younger than 50 years were more likely to progress (p = 0.046), whereas the patients with chest wall or upper-extremity tumors reported significantly more pain (p = 0.01).”

Source: [van Houdt et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31531797/)

> “Insomnia, unable to lean on tumour site, fatigue and pain were the most frequently reported symptoms for all DTF patients.”

Source: [Schut et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10315709/)

<a id="topic-2.2.1.6-4"></a>

### Neurological symptoms: nerve pain and paresthesia

| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Nerve pain (localized/radiating) | “22” | “6.00” |
| Muscle pain (localized/radiating) | “20” | “6.75” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “Symptomatic disease was ascertained based on documentation of symptoms, including tumor-related pain, paresthesia, fatigue, swelling, muscle weakness, loss of function (such as difficulty in moving limbs or walking), nausea, and fullness.”

Source: [Tan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13063223/)

<a id="topic-2.2.1.6-5"></a>

### Physical function: decreased range of motion and loss of mobility

> “Desmoid tumors (or aggressive fibromatosis) are locally infiltrative connective-tissue tumors that can arise in any anatomic location; they can be asymptomatic, or they can result in pain, deformity, swelling, and loss of mobility and/or threaten visceral organs with bowel perforation, hydronephrosis, neurovascular damage, and other complications.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Decreased range of motion | “21” | “4.00” |
| Stiffness | “10” | “3.00” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “Those with the current presence of DT at the time of survey completion reported significantly worse pain (dull pain, shooting pain), swelling around the tumor, and difficulty moving body areas near the tumor (compared with those without the current presence of DT).”

Source: [Lucas et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12522799/)

> “Depending on tumor size, aggressiveness of growth pattern and location, desmoid tumors can cause severe morbidities such as pain, disfigurement, internal bleeding and debilitating impairment on range of motion.”

Source: [SpringWorks Therapeutics Form 10-K (2025)](https://www.sec.gov/Archives/edgar/data/1773427/000177342725000010/swtx-20241231.htm)

<a id="topic-2.2.1.6-6"></a>

### Appearance: disfigurement and swelling

| Symptom elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Disfigurement/altered appearance | “25” | “5.00” |
| Swelling | “6” | “5.00” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.6-7"></a>

### Fatigue and sleep disturbance

> “In addition to pain and functional impairments, health care workers should also address fatigue, insomnia, anxiety, fear, and body dysmorphia.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

| Symptom or impact elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Fatigue | “20” | “5.00” |
| Lack of energy | “15” | “5.50” |
| Difficulty sleeping | “24” | “7.50” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

<a id="topic-2.2.1.6-8"></a>

### Intra-abdominal symptoms: nausea, early satiety, bowel obstruction, perforation, and hydronephrosis

> “Depending on its location, patients can present with pain, a loss of range of movement or immobility, bowel obstructions and/or perforations, hydronephrosis, and a host of other symptoms.”
> “As expected, the symptoms and impacts preliminarily show variation by anatomical location, as seen with abdominal desmoids, which cause nausea and early satiety.”

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

> “The HPN group was more likely to have advanced-stage disease and significantly higher incidence of chronic abdominal pain, narcotic dependency, bowel obstruction, ureteral obstruction, deep vein thrombosis, pulmonary embolism, fistulae, and sepsis (P < .05).”

Source: [Shatnawei et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23319384/)

<a id="topic-2.2.1.6-9"></a>

### Psychological symptoms: fear, anxiety, and depression

| Impact elicited in concept elicitation interviews (n = 31) | Frequency of mentions | Median disturbance rating |
| --- | --- | --- |
| Fear | “26” | “6.50” |
| Anxiety | “22” | “6.75” |
| Depression | “20” | “8.00” |
| Altered body image/function | “12” | “4.75” |

Source: [Gounder et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6980244/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
